Welcome to our dedicated page for Ovid Therapeutics news (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Ovid Therapeutics Inc (OVID) is a biopharmaceutical innovator developing therapies for rare neurological disorders, with a focus on epilepsy and seizure-related conditions. This page serves as the definitive source for Ovid Therapeutics news, providing investors and stakeholders with timely updates on clinical developments and corporate milestones.
Access official press releases and curated news covering drug development progress, clinical trial results, strategic partnerships, and regulatory updates. Our repository ensures you stay informed about Ovid’s pipeline advancements, including novel candidates targeting Angelman syndrome, fragile X syndrome, and rare epileptic encephalopathies.
Key updates include progress reports on first-in-class therapies, collaborations with industry leaders like Takeda, and insights into Ovid’s scientific approach. Bookmark this page to monitor developments in neurological treatment innovation and make data-driven decisions with direct access to primary source materials.
Ovid Therapeutics (NASDAQ: OVID) has provided business updates and first-quarter 2024 financial results. Key highlights include the completion of two Phase 3 trials by Takeda for soticlestat, expected to treat Lennox-Gastaut and Dravet syndromes, with topline data anticipated in H1 2024. A Phase 1 trial for OV888 (GV101) has concluded, showing no serious adverse events, with Phase 2 set to begin in H2 2024. Financials reveal cash and equivalents of $90.3 million, enough to support operations into H1 2026. Revenue for Q1 2024 was $148,000, up from $66,000 in Q1 2023, despite an increased net loss of $11.7 million.
Ovid Therapeutics Inc. will be participating in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024, at 3:00 p.m. ET. The company is focused on developing medicines for rare epilepsies and brain conditions. The event will be live webcasted and can be accessed through the Company’s website.
FAQ
What is the current stock price of Ovid Therapeutics (OVID)?
What is the market cap of Ovid Therapeutics (OVID)?
